Sublingual Immunotherapy Effectiveness: The Clinical Evidence

A standardized mean difference, or SMD, expresses the gap between two groups in standard-deviation units, allowing results from different trials and scales to be combined. The Cochrane review of 60 sublingual immunotherapy trials found an SMD of -0.49 for symptom scores versus placebo, where the negative sign means SLIT-treated patients had fewer symptoms than placebo patients. An SMD around -0.5 is conventionally interpreted as a moderate effect: meaningful and clinically relevant, with the groups still overlapping rather than being completely separated. In plain language, the average person on SLIT did noticeably better than the average person on placebo. It is solid evidence of benefit, not proof that every individual will respond.

Both are effective, and comparing them requires nuance. Subcutaneous immunotherapy (allergy shots) has a long, standardized evidence record, while sublingual immunotherapy has moderate-grade evidence from many trials, including the Cochrane analysis showing a significant effect versus placebo. Some head-to-head and indirect comparisons suggest shots may carry a modest edge for certain allergens, but results are not uniform, and confidence intervals often overlap. Rather than a blanket ranking, the responsible statement is that sublingual immunotherapy carries a lower risk of systemic reactions while subcutaneous has deeper evidence for some allergens. The most effective option for a given person depends on their allergens and is best decided with a licensed allergist.

Evidence grading considers consistency, study quality, and how directly trials measure outcomes. Sublingual immunotherapy earns a moderate grade because many randomized trials point the same direction, confirming a real benefit, but they vary in allergen, dose, treatment duration, and how they define and measure response. That heterogeneity introduces some uncertainty, which keeps the grade below the highest tier reserved for very large, uniform, low-bias evidence. Moderate grade is genuinely reassuring; it means the effect is reproducible and unlikely to be chance. It also signals appropriate caution: effectiveness varies between individuals, and outcomes cannot be guaranteed, so claims should be hedged rather than absolute.

The evidence differs in standardization. FDA-approved SLIT tablets, such as Grastek, Oralair, Ragwitek, and Odactra, went through dedicated trials for single allergens and carry well-characterized effectiveness data. Custom liquid drops are compounded for individualized, often multi-allergen treatment and are used off-label in the United States; their evidence base is meaningful but less standardized than the approved tablets. Both work through the same sublingual mechanism. The practical implication is that effectiveness expectations should be framed honestly: tablets have tightly defined trial data for specific allergens, while drops offer personalization supported by the broader moderate-grade SLIT literature. A licensed allergist can explain which approach best fits your particular sensitizations.

Realistic expectations center on meaningful reduction rather than elimination. The Cochrane symptom effect size of -0.49 versus placebo and the JAMA finding that 9 of 36 studies showed greater than 40% improvement both point to substantial but partial relief for many patients. Practically, that often looks like milder symptoms, fewer bad days during peak season, and less need for rescue antihistamines, built up over a multi-year course. It does not typically mean becoming completely allergy-free. Because effectiveness varies with allergen, dose, and adherence, your own result may fall anywhere along that range. Setting the goal as significant, lasting improvement gives a more accurate picture than expecting a total cure.